Introduction {#s1}
============

Pulmonary fibrosis, characterised by progressive and irreversible scar formation in the lung interstitium and by the gradual reduction in alveolar space, is the final stage of most interstitial lung diseases (ILDs) and can eventually lead to malfunction of gas exchange and subsequent respiratory failure. Its known causes (risk factors) include certain environmental exposures or insults, such as cigarette smoking and microaspiration \[[@C1]\]. Pulmonary fibrosis also is the common complication of some connective tissue diseases, with systemic sclerosis (scleroderma) and rheumatoid arthritis as the two prominent examples. When all known causes of ILD have been ruled out, this condition is called idiopathic pulmonary fibrosis (IPF). IPF represents the most prevalent and lethal form of ILD, and patients usually have a median survival of only 2--5 years after diagnosis \[[@C2], [@C3]\]. The 5-year survival rates in IPF are even lower than in the most types of aggressive cancer \[[@C4]\]. Despite that two pharmacological agents have recently entered clinical use for the treatment of IPF on the basis of their efficacy in reducing the decline in pulmonary function, huge challenges remain because these agents failed to improve mortality outcomes \[[@C5]--[@C7]\].

It has been generally accepted that some soluble cytokines, like transforming growth factor (TGF)-β and connective tissue growth factor, play active roles in the initiation of dysregulated fibrotic reactions in the lung \[[@C8], [@C9]\], with strategies targeting these molecules or related pathways being under clinical evaluation \[[@C10], [@C11]\]. Nevertheless, the fact is that IPF is diagnosed relatively late and the lung environment of such patients receiving management may have become dramatically different from that during initiation or early progression \[[@C12]\]. Several recent studies and reviews have suggested the concept that the excessively deposited extracellular matrix (ECM) proteins in the fibrotic lung may be drivers of, rather than bystanders in, the progression of pulmonary fibrosis \[[@C13]--[@C16]\]. Considering that collagens are major, as well as the most abundant, components of ECM, it is highly likely that those cell surface receptors responsible for transducing signals from collagens into the cells might be important intervention targets.

In mammals, there are primarily two diverse types of collagen receptor, the integrin and discoidin domain receptor (DDR) families \[[@C17], [@C18]\]. The DDR family, consisting of DDR1 and DDR2, are receptor tyrosine kinases and their intracellular domains can be induced into a sustained tyrosine-phosphorylated state in response to collagen binding, which ultimately triggers an array of signalling pathways and cellular effects \[[@C19], [@C20]\]. Recently, it was suggested that DDRs are also able to elicit influence on cells in a ligand binding-independent manner \[[@C21], [@C22]\]. Integrins are totally different from DDRs in that they are heterodimers formed by noncovalent association of one α subunit (of which there are at least 18) and one β subunit (of which there are at least eight), and do not have the kinase activity \[[@C23]\]. Among the 24 known αβ pairs, there are four different collagen-binding integrins: α1β1, α2β1, α10β1 and α11β1 \[[@C17], [@C24]\].

Currently, only four collagen receptors have been reported to be linked to the pathogenesis of lung fibrotic diseases: DDR1, DDR2, and α2β1 and α11β1 integrins. Compared to lung fibroblasts from normal individuals, those from IPF patients were found to express aberrantly low levels of α2β1 integrin, which were experimentally confirmed to result in a failure of integrin to induce protein phosphatase 2A as well as the inappropriate activation of the β-catenin proliferation signal pathway \[[@C25]\]. As for the contribution of α11β1 integrin to pulmonary fibrosis, it was documented that the expression of CIB1, which is a binding partner of integrin α11 subunit (ITGA11), was elevated in mouse fibrotic lung tissues and its overexpression can suppress the activation of human lung fibroblast cell lines \[[@C26]\]. Data from our laboratory and others demonstrated that the mice deficient in either *Ddr1* or *Ddr2* are both resistant to bleomycin-induced experimental pulmonary fibrosis \[[@C22], [@C27]\]. The detailed mechanism underlying DDR1 regulation of this type of pathological disorder remains unclear, whereas DDR2 has been proven to control the activation of lung myofibroblasts by mediating the signalling triggered by collagen and TGF-β \[[@C22]\].

Our preliminary findings derived from immunohistochemical examination of a very limited number of IPF samples hint that DDR2 expression in IPF lungs is much higher than that in healthy controls \[[@C22]\]. In view of the above research situation, several uncertainties remain. A first question is whether the expression signature of DDR2 in IPF can be reproduced in large quantities of clinical specimens or even in other types of ILD. The second question is that how is the expression abundance of the other five collagen receptor members in IPF. Another interesting and attractive issue may be whether there is one or several collagen receptors whose expression and function dominate in fibrotic lung diseases.

In the current study, we found that among the six members, the mRNA expression levels of only *ITGA11*, *DDR1* and *DDR2* in IPF patients dramatically exceed those in healthy controls, with this difference being most pronounced for *DDR2*.The sharp elevation of DDR2 expression in human fibrotic lung tissues could be further confirmed in the protein level. Therefore, our investigation suggests that DDR2 might represent a major collagen-recognising cell surface protein in human pulmonary fibrosis.

Methods {#s2}
=======

Collection of human ILD specimens {#s2a}
---------------------------------

All the ILD specimens were obtained from patients who had undergone lung transplantation surgery at the Key Laboratory of Organ Transplantation of Wuxi People\'s Hospital (Wuxi, PR China). The diagnosis of IPF was determined by each subject\'s primary pulmonologist according to American Thoracic Society/European Respiratory Society guidelines incorporating high-resolution computed tomography characteristics, surgical lung biopsy data and clinical exclusion of alternative causes of ILD. In addition to IPF (n=20), lung tissues of patients diagnosed with pulmonary fibrosis of other aetiologies (*i.e.* nonspecific interstitial pneumonia and connective tissue disease-associated ILD, *etc.*) were also included in this study (n=14). The diagnostic information for these non-IPF patients was based on multidisciplinary approach and provided in the [supplementary table](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00138-2016.figures-only#fig-data-supplementary-materials). The 10 healthy lung tissue samples were from organ donors diagnosed with brain death. Written consent for tissue donation for research purposes was obtained from each patient or the family members of healthy donors before tissue collection. The study protocol was approved by the institutional review boards of Guangzhou Medical University (Guangzhou, PR China), the Fourth Military Medical University (Xi\'an, PR China) and Wuxi People\'s Hospital.

Preparation of total RNA and protein samples {#s2b}
--------------------------------------------

For extraction of RNA and protein simultaneously, the lung tissues were ground with TRIzol Reagent (Invitrogen, Carlsbad, CA, USA). The aqueous phase was used to extract RNA through isopropanol and ethanol precipitation steps. The organic phase was subjected to protein extraction according to the manufacturer\'s instruction. Briefly, after isopropanol and ethanol precipitation, the centrifuged pellets were washed sequentially three times with a solution containing 0.3 M guanidine hydrochloride in 95% ethanol and once with pure ethanol. Finally, the obtained protein sediments were dissolved in protein sample buffer after vacuum drying.

Quantitative real-time PCR {#s2c}
--------------------------

cDNA was synthesised using the Super-Script II First-Stand Synthesis System (Invitrogen). Two-step quantitative real-time PCR (qPCR) with SYBR Green I (Takara, Shiga, Japan) labelling was conducted on a real-time thermocycler (Applied BioSystems, San Diego, CA, USA). The primer sequences used were as follows. Human *ITGA1*: GTCCAGTTGGGAGAGGTGAA (forward); CTCCATTTGGGTTGGTGACT (reverse); human *ITGA2*: GATTTGCGTGTGGACATCAG (forward); AAAGTCCGTCCTCACCACAG (reverse); human *ITGA10*: TCTTGGAGGTGGTTCAGACC (forward); AAAGAAGCCAAGCTTCCACA (reverse); human *ITGA11*: ACCCCATTTCCAAACAACAA (forward); CAGTACGGCTCTGTTGGTGA (reverse); human *DDR1*: GATTTCCCCCTTAATGTGCGT (forward); TGGCATCTGGCCGTAAGATC (reverse); human *DDR2*: CTCCCAGAATTTGCTCCAG (forward); GCCACATCTTTCCTGAGA (reverse); β-actin: TGGCACCCAGCACAATGAA (forward); TAAGTCATAGTCCGCCTAGAAGCA (reverse). The amplification programme was as follows: 95°C for 10 s, followed by 40 cycles of 95°C for 5 s and 60°C for 34 s. qPCR data were expressed as the mRNA expression level of the target gene relative to an internal reference control. Bar graphs represent the mean±[sd]{.smallcaps} of three individual experiments.

Immunoblot analysis {#s2d}
-------------------

The protein lysates were resolved by 10% SDS-PAGE and then transferred to nitrocellulose membranes (Amersham Biosciences, Little Chalfont, UK). After blocking with 5% bovine serum albumin in Tween 20--Tris-buffered saline, the membranes were incubated with primary antibodies, followed by incubation with horseradish peroxidase-labelled secondary antibodies (Cell Signaling Technology, Beverly, MA, USA). The protein bands were visualised using the ECL Western Blotting Detection Kit (GE Healthcare, Little Chalfont, UK). The primary antibodies used for immunoblot detection in this study were: DDR2 (1:1000; R&D Systems, Minneapolis, MN, USA); collagen I (1:1000; Abcam, Cambridge, MA, USA); fibronectin (1:100; Sigma-Aldrich, St Louis, MO, USA); phosphorylated DDR2 (1:500; R&D Systems); and tubulin (1:1000; Booster, Wuhan, PR China).

Immunohistochemical staining {#s2e}
----------------------------

For immunohistochemical detection of DDR2, paraffin sections (4 μm) were dewaxed and rehydrated through graded alcohol, then subjected to DDR2 antigen retrieval by high pressure cooking for 2 min in 10 mmol·L^−1^ citrate acid (pH 6.0). The endogenous peroxidase activity was cleared using 3% H~2~O~2~ in methanol for 10 min. The sections were incubated with normal goat serum at a dilution of 1:100 for 1 h. The antibody against human DDR2 was used at a dilution of 1:100. After incubation with the primary antibody or mouse IgG overnight at 4°C, the sections were washed in PBS and incubated with biotinylated goat anti-mouse IgG at a dilution of 1:200 and VECTASTAIN ABC Reagent (Vectastain Elite ABC kit; Vector Laboratories, Burlingame, CA, USA) at a dilution of 1:400 consecutively for 30 min each. Peroxidase activity was demonstrated by adding 3,3′-diaminobenzidine as a chromogen (Sigma-Aldrich). The sections were then counterstained with haematoxylin, followed by examination under a light microscope. Negative controls were made by using normal mouse IgG on all tissue slides.

Statistical analysis {#s2f}
--------------------

Statistical analyses were performed using the Statistical Product and Service Solutions software (IBM, Armonk, NY, USA). Independent-samples t-tests was used to examine the differences between the two groups of data. A two-tailed p-value of \<0.05 was considered significant.

Results {#s3}
=======

mRNA expression profiles of six collagen receptors in IPF {#s3a}
---------------------------------------------------------

Firstly, we conducted qPCR to compare the mRNA expression of the six collagen receptors between IPF and healthy donors. The expression levels of both ITGA1 and ITGA10 in IPF samples showed a slight decrease, whereas ITGA2 and ITGA11 were significantly upregulated, with mean fold changes of 2 and 5, respectively ([figure 1](#F1){ref-type="fig"}). Unlike the mRNA of *DDR1*, the IPF-associated elevation of which was, on average, merely approximately seven-fold with large variations among different individual specimens (range from 1.4- to 23.3-fold), that of *DDR2* reached up to 100-fold with little variation (range 59.3--191.8-fold) ([figure 2a](#F2){ref-type="fig"}). The disease-induced expression enhancement of *DDR2* also dramatically exceeded that of *DDR1* in non-IPF ILD ([figure 2b](#F2){ref-type="fig"}).

![mRNA expression of collagen-binding integrins in idiopathic pulmonary fibrosis (IPF) lungs. The lung tissue cDNA from 20 IPF patients and 10 healthy donors were subjected to quantitative real-time PCR analysis of the mRNA expression levels of a) integrin α1 (*ITGA1*), b) *ITGA2*, c) *ITGA10* and d) *ITGA11*, respectively. The graph indicates the expression level of the target gene relative to the reference gene β-actin. Bar graphs represent the mean±[sd]{.smallcaps} of three individual experiments.](00138-2016.01){#F1}

![Comparative expression of discoidin domain receptors (DDRs) between healthy lung tissues and those from different types of interstitial lung disease (ILD): a) idiopathic pulmonary fibrosis (IPF) and b) non-IPF ILD. The disease-induced elevation of *DDR2* dramatically exceeds that of *DDR1* in both IPF and non-IPF ILD. Bar graphs represent the mean±[sd]{.smallcaps} of three individual experiments.](00138-2016.02){#F2}

Protein expression of DDR2 in ILD {#s3b}
---------------------------------

On the basis of the above data, we investigated the protein abundance of DDR2 by Western blotting. The results showed that the lung homogenates from 20 IPF patients ubiquitously contained much more DDR2 protein as well as the fibrotic markers collagen I and fibronectin than those from 10 normal subjects ([figure 3a](#F3){ref-type="fig"}). The expression level of DDR2 in non-IPF ILD cases also significantly exceeded that in the healthy group, albeit not as high as in IPF ([figure 3b](#F3){ref-type="fig"}).

![Discoidin domain receptor (DDR)2 protein was highly expressed in the lungs of patients with interstitial lung disease (ILD). The total lung proteins were extracted simultaneously with RNA by use of the standard TRIzol Reagent protocol and then subjected to immunoblot analysis of DDR2, collagen (Col) I, fibronectin and tubulin. DDR2 expression was greatly increased in both a) idiopathic pulmonary fibrosis (IPF) and b) non-IPF ILD.](00138-2016.03){#F3}

Localisation and activation status of DDR2 in ILD {#s3c}
-------------------------------------------------

Immunohistochemical experiments were further performed in order to locate the DDR2-expressing cells. Consistent to our recent findings in IPF \[[@C22]\], DDR2 was found to be highly expressed by the cells that display spindle or fibroblastic shapes in non-IPF ILD ([figure 4](#F4){ref-type="fig"}).

![Representative images of immunohistochemical staining of discoidin domain receptor (DDR)2 in interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). The paraffin lung tissue sections from patients with non-IPF ILD were immunostained with a) mouse IgG or b--d) antibody against DDR2. The green arrows show those cells with a fibroblastic shape. Scale bars=20 μm.](00138-2016.04){#F4}

The DDR2 proteins on the cell surface of these pathological fibroblasts theoretically have the chance to be triggered to activation by the abundantly accumulated fibrillar collagens within the fibrotic lesions that serve as its potent ligands \[[@C20]\]. In order to test this possibility, immunoblots were probed with a specific antibody against the tyrosine phosphorylated form of DDR2. The expected bands were more or less observable in both disease groups but were undetectable in healthy controls. Moreover, the phosphorylation level of DDR2 in IPF was much higher than that in non-IPF ILD ([figure 5](#F5){ref-type="fig"}).

![Phosphorylation levels of discoidin domain receptor (DDR)2. The lung tissue protein homogenates from the indicated interstitial lung disease (ILD) patients were separated by SDS-PAGE and then probed by Western blotting with a specific antibody against the phosphorylated form of DDR2 (p-DDR2). Idiopathic pulmonary fibrosis (IPF) patients showed the most intense level of DDR2 phosphorylation compared with healthy individuals or non-IPF ILD patients.](00138-2016.05){#F5}

Discussion {#s4}
==========

Although four members of the family of collagen receptors (DDR1, DDR2, and α2β1 and α11β1 integrins) have been reported to be associated with the pathogenesis of lung fibrosis \[[@C22], [@C25], [@C27], [@C28]\], it remains unclear whether they and the other two members have similar abundance patterns or play equal roles in this type of disease. In this investigation, we revealed for the first time that, among the six collagen receptors, *DDR2* is the only gene whose transcription and expression display sharp differences between IPF patients and healthy individuals. Considering that DDR2 plays a profibrotic role in experimental pulmonary fibrosis \[[@C22]\], our current data further provide clinical evidence that this unique collagen receptor can be viewed as a promising target for diagnosis and therapy of end-stage IPF.

The immunohistochemical findings from a previous publication showed that the expression level of ITGA1 in IPF fibroblastic foci was remarkably lower than that in the epithelial cells overlying the fibroblastic foci \[[@C25]\]. This result perfectly accounts for the tiny increase in ITGA2 observed in our study since qPCR experiments were conducted by use of whole-lung homogenates, which may contain both ITGA2-low expressing fibroblasts and ITGA2-high expressing epithelial cells. Due to the negative influence of ITGA2 signalling on IPF fibroblast proliferation \[[@C25]\], we speculate that it might not be an ideal therapeutic target for IPF.

According to the data here presented, ITGA11 appears to be the only collagen-binding integrin that is dramatically upregulated in all IPF samples used. This phenomenon seems to conform to the observations documented in two previous literature reports. One described that the expression of ITGA11 is enhanced in TGF-β-treated lung fibroblasts \[[@C28]\]. The other recorded that the level of an ITGA11 binding partner was elevated in mouse fibrotic lung tissues \[[@C26]\]. We also noticed that the fold increase in *ITGA11* mRNA expression in IPF *versus* controls was relatively close between patients. A possible explanation for this consistent upregulation may be that ITGA11 expression is predominantly restricted to fibroblasts \[[@C29]\]. As for the functional role of ITGA11 in lung fibroblasts, the only clue is the observation that its binding protein suppresses myofibroblast formation \[[@C26]\].

Established studies of the contribution of collagen-binding integrins to pulmonary fibrosis have merely centred around analysis of histological expression or of the *in vitro* cell behaviours, while those of the DDR family predominantly concentrated on the identification of the pathological phenotypes of genetic mouse models. Mice deficient in either *Ddr1* or *Ddr2* were demonstrated to be resistant to the induction of pulmonary fibrosis \[[@C22], [@C27]\]. With regard to the mechanisms involved, DDR1 was considered primarily to regulate the function of epithelial cells and macrophages \[[@C27]\]. Collagen I-induced expression of DDR1 in lung fibroblasts, albeit positive, was reported to rely on the activation of DDR2 signalling \[[@C30]\]. The important role of DDR2 in lung fibroblasts was recently strengthened by the results from our laboratory showing that, *in vitro*, its expression in this type of cells could be sharply induced by TGF-β treatment and its deficiency impedes the cell acquisition of myofibroblastic features \[[@C22]\]. These earlier experimental data exactly accord with our current findings that the fibroblastic cell shapes within the lung tissues of different types of ILD were strongly stained for DDR2. From the view of the type of cells they can influence, it can be conceived that DDR2 tended to be more suitable than DDR1 to be used as a therapeutic target for IPF in that myofibroblasts are major effector cells of fibrotic reaction.

DDR2 also possesses several other advantages that make it an excellent alternative molecule in designing therapeutic options against ILD. Firstly, in addition to fibrotic reaction, DDR2 can also promote the angiogenic process during pulmonary fibrosis through modulation of both endothelial cell activity and myofibroblast expression of vascular endothelial growth factor (VEGF) \[[@C22], [@C31]\]. This feature is particularly useful since nintedanib, a triple angiokinase inhibitor, has become the first approved drug for IPF treatment \[[@C32]\]. Secondly, we recently revealed that DDR2 not only mediates fibrillar collagen-induced signalling but is also indispensable for TGF-β-triggered activation of p38 and Akt as well as lung fibroblast conversion into myofibroblasts \[[@C22]\]. This function of DDR2 implies that targeting its synergistic cooperation with the TGF-β cascade might also produce effects on the initiation of the fibrotic process. Thirdly, certain functions of DDR2, at least those requiring collagen binding and subsequent phosphorylation of DDR2, could be blocked by either neutralising antibody or kinase inhibitors. Fourthly, accumulating evidence indicates that DDR2 expression is stress inducible, which is reflected by its upregulation in response to multiple stimulation conditions such as hypoxia \[[@C26], [@C33]\], TGF-β \[[@C22]\] and proangiogenic cytokines \[[@C34]\]. This conclusion can be additionally supported by the sharp difference in DDR2 abundance between normal and IPF lungs, as disclosed by this study. The low or absent expression of DDR2 in resting cells signifies that targeting strategies against this receptor might be relatively safe.

In summary, our study reconciled the uncertainty regarding the status of the six collagen receptors in IPF, and suggests that DDR2 might be the main collagen receptor that is suitable for both diagnosis and therapy of this disease.
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